How Risky Is Too Risky?

Would a Big Pharma company ever sell a product like Tysabri?

When Biogen Idec was up for sale last year, Big Pharma passed.

There were plenty of reasons not to do the deal: the price would be steep, and interlocking change in control...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet